Barbora Kubešová. Principles of screening  Simple, feasible  High sensitivity –detects disease, specifity – negative in unaffected individual  Ekonomically.

Slides:



Advertisements
Similar presentations
Examples of Sound Screening:
Advertisements

SOUTH AUSTRALIAN MATERNAL SERUM ANTENATAL SCREENING (SAMSAS© ) PROGRAM
Reproductive Technologies & Counseling Patricia Kloser, MD, MPH, FACP Professor of Medicine Professor of Public Health June 2006 UMDNJ, a Local Performance.
Antenatal Screening Dr Emma Parry CMFM
Medical Statistics Joan Morris Professor of Medical Statistics Goldsmiths Lecture 2014.
Screening “the systematic application of a test procedure to identify individuals at sufficient risk to warrant diagnostic investigations” CVS 12wks Amniocentesis.
Antenatal Screening Mehreen Yousaf GP STS.
Genetic Testing in Pregnancy
Second-trimester maternal serum screening
Fetal Testing During Pregnancy
Towards Early Biochemical Screening for Fetal Aneuploidy in the First Trimester Niels Tørring 1, Olav B Petersen 2 1. Department of Clinical Biochemistry,
BROWN Prenatal Screening for Trisomy 21: Recent Advances and Guidelines Jacob Canick, PhD Alpert Medical School of Brown University Women & Infants Hospital.
Genetics and Primary Care
Prenatal Testing for Down Syndrome: Where Do We Stand Today? David B. Fox, MD Riverside Methodist Hospital.
Prenatal Genetics OG Supplemental Information Drs. Deborah Driscoll and Michael Mennuti.
Antenatal Care DR. Yasir Katib MBBS, FRCSC Perinatologest.
Screening for fetal Down’s Syndrome – Improving efficacy and efficiency.
NON – INVASIVE PRENATAL TESTING
Enhanced Prenatal Screening Program
Best Start - Prenatal Education Program Prenatal Care.
IN THE NAME OF GOD. CRITICALLY APPRAISED TOPIC If there is a Non-invasive prenatal testing for aneuploidies with low FPR at first trimester? If we can.
By : Drs Barati Drs Mohammadjafari Drs Masihi Drs aadati Drs Shahbazian DRS Zamanpoor(resident)
Prenatal Testing.
Testing during pregnancy There are many tests during pregnancy. In pairs have a think about what type of tests take place during pregnancy. Brainstorm.
Pregnancy & Newborn Screening Developments
Photo: courtesy Travel Alberta.  The provision of information for individuals  Women have the right to access information about the health of their.
 * Testing for diseases/conditions in a fetus or embryo before it is born.  * Aim is to detect birth defects  * Multiple tests that can be done each.
First Trimester Screening
Objectives Goals of the week scanGoals of the week scan Fetal nuchal translucency in the detection of aneuploidyFetal nuchal translucency in.
OBesity Project Pregnancy.
National Women’s Screening for Aneuploidy Dr Emma Parry CMFM Clinical Director Maternal-Fetal Medicine National Women’s Health.
Hyper / Hypo Disorders. HYPEREMESIS GRAVIDARIUM **Pernicious vomiting during Pregnancy Pregnancy.
In the name of god First Trimester Screening Dr.M.Moradi.
Is Antenatal Care Worthwhile? Max Brinsmead MB BS PhD May 2015.
DIABETES. Type I Diabetes: Preconception Counseling The most important aspect of the management of the Type I diabetic during pregnancy is preconception.
Prenatal Diagnosis of Congenital Malformations for Undergraduates
Epidemiological Monitoring and Quality Control of Nuchal Translucency Jack Canick Intensive Course on Screening for Down’s Syndrome Wolfson Institute of.
VI. Hrvatski kongres o ginekološkoj endokrinologiji, humanoj reprodukciji i menopavzi s međunarodnim sudjelovanjem , Brijuni DARIJA STRAH.
ACB Training Course- Plymouth Down’s syndrome screening David Worthington (Laboratory Advisor - National Screening Programme)
Vajiheh Marsoosi, M.D Associate Professor of TUMS Shariati Hospital.
The New Prenatal Screening Tests Langley Memorial Hospital Grand Rounds November 8, 2007 Ken Seethram, MD, FRCSC, FACOG Obstetrics and Gynecology, Burnaby.
The Role of Prenatal screening as part of Routine Obstetric Care
Antepartum Hemorrhage Family Medicine Specialist CME University of Health Sciences.
Intro Until recently, couples had to choose between taking the risk or considering other options Over the past three decades, prenatal diagnosis-the ability.
Conceptual & technical advances in Down’s syndrome screening Howard Cuckle
Screening for Down’s syndrome
HHHoldorf PhD, MPA, RDMS (Ob/Gyn, Ab, BR), RVT, LRT(AS)
Barbora Kubešová. Sonoembryology 5 wks gestation - gestational sac 2-3mm – first visualisation Double decidual sac sign –hyperechogenic excentric localisation.
Genetic Testing in Pregnancy Lisbeth M. Lazaron, MD March 2013.
Genetic Counseling and Prenatal Diagnosis Dr. Hassan Nasrat FRCS & FRCOG Professor Dept. Obstetrics & Gynecology King Abdulaziz University Hospital.
Antenatal Case Study Serah Mungai & Hywel Mackey.
Prenatal Screening and Diagnosis. What is Prenatal Diagnosis?  In-utero detection of fetal anomalies General population risk is 3-5% for any birth defect.
UOG Journal Club: June 2017 Multicenter screening for pre-eclampsia by maternal factors and biomarkers at 11–13 weeks’ gestation: comparison with NICE.
بنام خدا.
BIOCHEMICAL MARKERS OF PRENATAL DIAGNOSIS
Intro Until recently, couples had to choose between taking the risk or considering other options Over the past three decades, prenatal diagnosis-the.
UOG Journal Club: March 2016
Antenatal Screening Rebecca Sykes.
Intrahepatic cholestasis of pregnancy
Overview of Prenatal Care
Aneuploidy and NTD screening
Jeffrey A. Kuller, MD; Sean C. Blackwell, MD
Gestational Diabetes Lab 4.
غربالگری ناهنجاریهای جنین
Prenatal Screening for Genetic Conditions
Biomarkers in Early Pregnancy
guidance on antenatal screening
Ultrasound in fetal screening ( Down syndrome,…)
NON – INVASIVE PRENATAL TESTING
IN THE NAME OF GOD First trimester screening for aneuploidy
Presentation transcript:

Barbora Kubešová

Principles of screening  Simple, feasible  High sensitivity –detects disease, specifity – negative in unaffected individual  Ekonomically profitable, available  No negative side effects  Identification of the marker  Standartised examination  Quality control

Screening of aneuploidias in pregnancy  Marker of aneuplodia – different prevalence in an aneuploide and euploide population  Strenght of a marker increases with the increasing difference of prevalencies  Assessment if the likelihood of the presence of a marker is influenced by maternal or fetal factors  Assessement of several markers – ascertain their reciprocal dependency  Determination of a „cut off level“, efectivity of detection – detection rate, false positivity

Biochemical screening in pregnancy  10 wks PAPP A – pregnancy associated protein A HCG –free b unit of choriogonadotropin hormon  16 wks Double, triple test, quadruple test AFP – alfa-fetoprotein HCG – free b unit of choriogonadotropin hormon Estriol, Inhibin

First trimestr screening in pregnancy Combines ultrasound screening and examination of maternal serum markers Measurement NT provides information about other fetal affections than aneuploidias Assessment of fetal anatomy Assessment of gestational age - important for the management of pregnancy

Algorythme of I.trim. screening Each marker has it´s likelihood ratio LR /ratio of prevalence in an eu-aneuploide population/ Quantitative parametres – NT,fetal HR, FMF angle, biochemical analytes ….separation of the group with a high and low risk= cut off values Quantitative parametres– NB,DV,TR – soft markers, assessment of their presence or absence The pregnant pacient has an a priori risk – back ground risk – usually the age of the pregnant patient

Combined test in the I.trimestre  Assessment of risk of T21, T18, T13 Patient´s age PAPP-A, HCG blood screen in 9.-10wk– examined in a FMF – fetal medicine foundation certified laboratory US - 12wk assessment of CRL, NT – nuchal transluscency – certified sonographers Calculation on a FMF software Astraia Detection 90%, FP – false positive rate < 5%

Contingent test in I.trimestre c ombined test /age, biochemistry, NT / 1:50 +more 1:51 - 1:1000 less than 1:1000 NB,TR,DV,FA minor markery >1:100 < 1:100 CVS, AMC US 20wks Detection 95%, FP 2-3%

Screening of open defects of the neural tube Intracranial translucency IT Dg - NTD – open spinal dysrafismus /OSD

Screening of preeclampsie in I. trimestre Personal history BMI,age,etnicity, parity, smoking Pulsatility index a.uterina PAPP A - pregnancy asociated protein A Placental growth factor – PIGF

Screening of glucose intolerance in pregnancy  I.trimestre glycaemia less - 5,5mmol/l  From 24 wks- maximal effect of anti-insuline hormones  OGTT oral glucose tolerance test venous blood withdrawal < 5,5 mmol/l 75g glucose load glycaemia after 2 hrs values < 7,7 mmol/l Elevated values = gestational diabetes mellitus 3-6months after delivery check-up OGTT

Screening of infections – B group Streptococcus – Str. agalactiae  I.trimestre HIV, HBsAg,BWR  II.trimestru HBsAG  vaginal smear, rectum – detection of group B Gram positive Streptococcus  GBS neonatal infection within first 24hrs of life –acute sepsis, pneumonia, late form of meningitis, osteomyelitis  GBS+ mothers aplication of PNC G, cefalosporin i.v. at the beginning of labour, 4 hours apriori of ARM – artificial rupture of membranes

Screening of risk of premature delivery History Cervicometry – measurement of lenght of cervical canal, assessemnt of – funnelingu Values below 25mm higher risk

Screening in gynaecology Screening of cervical cancer Screening of endometrial cancer Screening of breast cancer - reimbursed by health insurance from the age of 45yrs, 2 yearly

Screening of cervical cancer  Onkological cytology Kolposkopia + HPV testation – prebioptic methods

Screening of endometrial cancer Transvaginal sonography Measurement of width of endometrium– different in pre-postmenopausal patients Assessment of echogenicity, borders –juntion zone

Thank you for your attention